2025³â 07¿ù 23ÀÏ ¼ö¿äÀÏ
 
 
  ÇöÀçÀ§Ä¡ > ´º½ºÁö´åÄÄ > Business

·£¼¶¿þ¾îºÎÅÍ µÅÁöµµ»ì±îÁö... ³ë·ÃÇØÁø »ç±âÇà°¢

 

Á¤Ä¡

 

°æÁ¦

 

»çȸ

 

»ýȰ

 

¹®È­

 

±¹Á¦

 

°úÇбâ¼ú

 

¿¬¿¹

 

½ºÆ÷Ã÷

 

ÀÚµ¿Â÷

 

ºÎµ¿»ê

 

°æ¿µ

 

¿µ¾÷

 

¹Ìµð¾î

 

½Å»óǰ

 

±³À°

 

ÇÐȸ

 

½Å°£

 

°øÁö»çÇ×

 

Ä®·³

 

Ä·ÆäÀÎ
Çѻ츲 ¡®¿ì¸®´Â ÇѽҸ²¡¯ ½Ò ¼Òºñ Ä·ÆäÀÎ ½Ã...
1000¸¸¿øÂ¥¸® Àΰø¿Í¿ì, °Ç°­º¸Çè Áö¿ø ¡®Æò...
- - - - - - -
 

Brii Biosciences Closes US$155 Million Series C Financing

Financing led by Invesco Developing Markets Fund, joined by a syndicate of new and current investors
´º½ºÀÏÀÚ: 2021-03-26

Proceeds will support accelerating clinical development programs in the United States and China

DURHAM, N.C. & BEIJING-- March 26, 2021 -- Brii Biosciences (“Brii Bio”), a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burden, today announced completion of a Series C financing of US$155 million. The financing, participated by existing and new investors, was led by Invesco Developing Markets Fund, with significant additional funding provided by GIC and another global leading investment management organization, followed by Lake Bleu Capital and an Asia-based leading investment organization, as well as three current investors.

Proceeds from the financing will be used to advance Brii Bio’s broad infectious diseases pipeline as well as the company’s CNS program.

“Since our founding in 2018, Brii Bio has made tremendous progress toward our mission to accelerate the development and delivery of breakthrough medicines through partnerships and our own insight in highly differentiated medicine discovery,” said Zhi Hong, Ph.D., CEO of Brii Bio. “As we work to address some of the world’s biggest public health issues and disease burdens, we are pleased and honored to have the support of investors who share our mission to discover, develop and deliver innovative treatments for patients not only in China, but throughout the world.”

Brii Bio is currently conducting clinical studies in multiple infectious diseases, and is preparing to enter clinical-stage research in diseases of the central nervous system. The company’s programs include:

· HBV: Initiation of a phase 2 study of BRII-835 (VIR-2218) in combination with BRII-179 (VBI-2601) in patients who are chronically infected with HBV is planned for March 2021, and will be the subject of a separate announcement.

· COVID-19 antibody therapies: BRII-196 and BRII-198, non-competing SARS-CoV-2 neutralizing antibodies are part of the Phase 2/3 studies under ACTIV-2 master protocols, sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) of the U.S. National Institutes of Health (NIH).

· Multi-drug resistant Gram-negative bacterial infections: BRII-636 (OMNIvanceTM), BRII-672 (ORAvanceTM) and BRII-693 (QPX-9003) are potent antibiotics against WHO-designated critical pathogens for the treatment of carbapenemase producing Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii.

· New HIV treatment options - Once Weekly Single Tablet Regimen (QW STR): phase 1 clinical study for BRII-778 has started and a U.S IND for BRII-732 was submitted in March. The company will investigate the potential of prolonged dosing interval for treatment of people who live with HIV.

· Novel treatment for central nervous system (CNS) disease: The phase 1 clinical trials for BRII-296 will begin shortly under a U.S. IND.



 Àüü´º½º¸ñ·ÏÀ¸·Î

LG Announces Ambition To Become Top-Tier Global HVAC Solution Provider
CSC Research Finds 40% of Enterprises Could Be at Risk of an Outage Due to SSL Expiration
Esri¡¯s ArcGIS Basemaps Power Dataminr First Alert for Enhanced Real-Time Event Detection and Awareness
Autonomous Agents Set to Revolutionize Transportation Management
Copeland Releases First Global Impact Report Showcasing Sustainability Leadership and Purpose-Driven Innovation
Andersen Consulting Adds Collaborating Firm GMS
Interactive Brokers Debuts IBKR InvestMentor - A Free Microlearning App to Educate the Next Generation of Investors

 

Lifezone Metals Files the Feasibility Study Technical Report Summary f...
Venture Global and SEFE Announce Expansion of LNG Partnership
Cirium Announces New Global Head of Cirium Ascend Consultancy
Andersen Consulting Advances Cybersecurity Presence with 10Guards
MultiBank Group Announces Early Access Waitlist for Pioneering $MBG To...
CEOs of The LYCRA Company and Qore¢ç Join Global Fashion Summit Lineup
APAC Regulatory Complexity Creates 29% Higher Workload for Multination...

 


°øÁö»çÇ×
´º½ºÁö ÇÑÀÚ Ç¥±â¿¡ ´ë¸¸½Ä À½Â÷ Ç¥±â '纽ÞÙó¢ ´Ï¿ì½ÃÁö' º´±â
º£³×ÇÁ·Ò º£³×ÀÎÅõ Áß¹® Ç¥±â 宝Ò¬ÜØÙÌ 宝Ò¬ì×öõ(ÜÄÒ¬ÜØÙÌ ÜÄ...
¹Ìµð¾î¾Æ¿ì¾î Mediaour ØÚ体ä²们 ØÚô÷ä²Ùú MO ¿¥¿À ØÚä² ØÚä²
¾Ë¸®¿ìºê Alliuv ä¹备: ä¹联êó备, ¾Ë¶ã Althle ä¹÷åìÌ
¾Ë¸®¾Ë Allial Áß¹® Ç¥±â ä¹××尔 ä¹××ì³
´ºÆÛ½ºÆ® New1st Áß¹® Ç¥±â 纽ììãæ(¹øÃ¼ Òïììãæ), N1 纽1
¿£ÄÚ½º¸ð½º : À̾¾ 'EnCosmos : EC' Áß¹® Ç¥±â ì¤ñµ
¾ÆÀ̵ð¾î·Ð Idearon Áß¹® Ç¥±â ì¤îè论 ì¤îèÖå
¹ÙÀÌ¿ÀÀÌ´Ï Bioini Áß¹® Ç¥±â ù±药研 ù±å·æÚ
¿À½ºÇÁ·Ò Ausfrom 奥ÞÙÜØÙÌ, À£ÇÁ·Ò Welfrom 卫ÜØÙÌ
¿¡³ÊÇÁ·Ò Enerfrom 额ÒöÜØÙÌ ¿¡³ÊÀ¯ºñ Eneruv 额Òöêó备
¾ËÇÁ·Ò Alfrom Áß¹® Ç¥±â ä¹尔ÜØÙÌ ä¹ì³ÜØÙÌ

 

ȸ»ç¼Ò°³ | ÀÎÀçä¿ë | ÀÌ¿ë¾à°ü | °³ÀÎÁ¤º¸Ãë±Þ¹æÄ§ | û¼Ò³âº¸È£Á¤Ã¥ | Ã¥ÀÓÇѰè¿Í ¹ýÀû°íÁö | À̸ÞÀÏÁÖ¼Ò¹«´Ü¼öÁý°ÅºÎ | °í°´¼¾ÅÍ

±â»çÁ¦º¸ À̸ÞÀÏ news@newsji.com, ÀüÈ­ 050 2222 0002, ÆÑ½º 050 2222 0111, ÁÖ¼Ò : ¼­¿ï ±¸·Î±¸ °¡¸¶»ê·Î 27±æ 60 1-37È£

ÀÎÅͳݴº½º¼­ºñ½º»ç¾÷µî·Ï : ¼­¿ï ÀÚ00447, µî·ÏÀÏÀÚ : 2013.12.23., ´º½º¹è¿­ ¹× û¼Ò³âº¸È£ÀÇ Ã¥ÀÓ : ´ëÇ¥ CEO

Copyright ¨Ï All rights reserved..